MedComm, Volume 7, Issue 10, October 2026.BTK inhibitors suppress malignant B‐cell signaling while simultaneously reshaping immune regulation through effects on T cells and the tumor microenvironment. These mechanisms support combination immunotherapy strategies and also underlie the expanding application of BTK inhibitors in solid tumors, autoimmune and inflammatory diseases.
Miao Sun, Dengju Li, Jia Wei
wiley +1 more source
Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade. [PDF]
Front OncolPoovathum Parambil AS +3 more
europepmc +1 more source
KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine
MedComm, Volume 7, Issue 10, October 2026.KRAS‐mutant cancers are therapeutically shaped by both allele identity and tumor context. Direct KRAS inhibition has achieved the greatest clinical success in KRAS G12C‐mutant NSCLC, whereas colorectal cancer often requires EGFR cotargeting and pancreatic cancer remains constrained by stromal and metabolic barriers. Shared resistance mechanisms include
Jiaying Cai +18 more
wiley +1 more source
Anti-Human Epidermal Growth Factor Receptor 2 therapies in metastatic colorectal cancer: a systematic review and meta-analysis. [PDF]
OncologistRota S +11 more
europepmc +1 more source
Nano Select, Volume 7, Issue 10, October 2026.Surface‐modified niosomes are introduced as multifunctional nanoparticles for precision tumor treatment that combine hydrophilic and lipophilic drug encapsulation with ligand‐based targeting via antibodies, peptides, transferrin, and folic acid. This modification leads to increased tumor selectivity, facilitates cell entry, and enables enhanced ...
Narges Sahraei +3 more
wiley +1 more source
Strategy for modular assembly of tetravalent, multispecific antibodies
Protein Science, Volume 35, Issue 10, October 2026.Abstract Multispecific, multivalent antibodies (Abs) are a burgeoning class of drugs that dramatically expand the pharmacological repertoire beyond traditional therapeutic Abs. Here, we present a simple, modular approach to developing multispecific, multivalent Abs based on a Fab‐phage library with a single light chain.
Evan Mallette +12 more
wiley +1 more source
Residual disease in HER2-positive early breast cancer: are we escalating the RIGHT patients to T-DM1 or T-DXd? [PDF]
Transl Cancer ResTjalma W, Papadimitriou K.
europepmc +1 more source
Cancer Science, Volume 117, Issue 10, Page 2676-2692, October 2026.KYNU is upregulated in gastric cancer cells and activates the PI3K/Akt pathway, leading to PF4 secretion. PF4 drives nonclassical macrophage polarization with high expression of S100A8 and MMP7, which promotes tumor proliferation, migration, and invasion while suppressing phagocytosis, thereby accelerating gastric cancer progression.
Xilun Cui +4 more
wiley +1 more source
Trastuzumab-TKI combination in HER2-Positive tumors: a FAERS-Based safety profile and multimodal analysis of Tanespimycin's role in enhancing targeting of the HSP90AA1-PI3K-Akt-mTOR axis. [PDF]
Front PharmacolChen X, Han X, Zhang Y, Cao J, Wang X.
europepmc +1 more source
Harnessing Quantitative Medicine to Advance Oncology Drug Development
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Oncology drug development continues to have a high attrition rate despite major advances in therapeutic modalities such as antibody‐drug conjugates, bispecific antibodies, cell therapies, and cancer vaccines. Critical development decisions are often made under substantial uncertainty, creating a need for quantitative approaches that integrate ...
Benjamin Wu +3 more
wiley +1 more source